Beneficial Effects of 6-Month Supplementation with Omega-3 Acids on Selected Inflammatory Markers in Patients with Chronic Kidney Disease Stages 1–3

Table 2

Characteristics of the studied group of patients with CKD 1, CKD 2, and CKD 3 at baseline and after supplementation with omega-3 acid.

Parameter	CKD 1	CKD 2	CKD 3	ANOVA
Gender
Women/men	14/15	15/17	11/15
Age (years)
Baseline
Postintervention
BMI (kg/m^2)
Baseline
Postintervention
Waist circumference (cm)
Baseline
Postintervention
Hip circumference (cm)
Baseline
Postintervention
Creatinine (mg/dl)
Baseline
Postintervention
eGFR CKD-EPI (ml/min/1.73 m^2)
Baseline
Postintervention
ALA (mg/100 ml)
Baseline	1.36 (0.96; 2.47)	1.98 (1.48; 2.57)	1.65 (1.11; 2.77)
Postintervention	3.03	3.22	2.82
EPA (mg/100 ml)
Baseline
Postintervention
DHA (mg/100 ml)
Baseline
Postintervention
CRP (mg/l)
Baseline	0.28 (0.10; 1.06)	1.67	1.17
Postintervention	0.77	2.13 (0.61; 3.22)	0.99 (0.46; 2.30)
WBC (10^3/µl)
Baseline
Postintervention
MCP-1 serum (pg/dl)
Baseline
Postintervention
MCP-1 urinary excretion (ng/24 h)
Baseline	362.6 (275.8; 695.2)	432.8 (263.2; 614.1)	458.4 (311.6; 697.8)
Postintervention	354.63 (114.8; 481.5)	251.1	329.5 (259.2; 468.8)

ALA: alpha-linolenic acid; BMI: body mass index; CRP: C-reactive protein; DHA: docosahexaenoic acid; eGFR: estimated glomerular filtration rate; EPA: eicosapentaenoic acid; MCP-1 serum: monocyte chemotactic protein 1 in serum; MCP-1 urinary excretion: 24-hour urinary excretion of monocyte chemotactic protein 1; WBC: white blood cells. after versus before; after versus before; versus CKD 1; versus CKD 1; versus CKD 2; versus CKD 2; versus CKD 1.